NASDAQ · Biotechnology

ADMA (ADMA) Stock

$8.71 -0.91% NASDAQ: ADMA Healthcare

Valuation

MetricValue
Price$8.71
Market Cap$2.02B
P/E Ratio12.17
P/B Ratio4.93
P/S Ratio3.76
EPS (TTM)$0.60
52-Week High$20.46
52-Week Low$7.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE43.30%
ROA21.99%
ROCE40.04%
Gross Margin61.27%
Operating Margin40.57%
Net Margin32.43%
Debt/Equity0.52
Current Ratio6.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$81.0M$154.0M$258.0M$426.0M$510.0M
Operating Profit$-58.0M$-39.0M$22.0M$139.0M$191.0M
Net Profit$-72.0M$-66.0M$-28.0M$198.0M$147.0M
EPS$-0.61$-0.43$-0.13$0.81$0.60
Op Margin-72.1%-25.6%8.4%32.6%37.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$276.0M$348.0M$329.0M$489.0M$624.0M
Total Liabilities$135.0M$196.0M$194.0M$140.0M$147.0M
Cash$51.0M$87.0M$51.0M$103.0M$88.0M
Borrowings$103.0M$154.0M$141.0M$82.0M$80.0M

Latest News

ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations Simply Wall St. · Jul 15, 2026 ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run Simply Wall St. · Jul 15, 2026 ADMA: Lowering target price to $8.00 Argus Research · Jul 15, 2026 Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights Zacks · Jul 13, 2026 Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? Zacks · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-112.0M$-60.0M$9.0M$119.0M$50.0M
Investing Cash Flow$-27.0M$-28.0M$-10.0M$-17.0M$-44.0M
Financing Cash Flow$0$-8.0M$-15.0M$-6.0M$-44.0M
Net Cash Flow$-5.0M$35.0M$-35.0M$52.0M$-16.0M
Free Cash Flow$-126.0M$-73.0M$4.0M$110.0M$28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA203.19
FCF Yield5.63%
Quick Ratio3.93
Interest Coverage27.29
Return 1Y-52.03%
Return 3Y121.18%
Return 5Y412.42%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $29.21 +2.67% 8.94 $5.00B 0.00%
BLTEBelite Bio, Inc $157.14 -2.45% -61.62 $6.30B 0.00%
CRNX $83.81 -0.09% -8.57 $8.87B 0.00%
DYN $25.97 +2.89% -6.05 $4.85B 0.00%
LGND $293.15 -2.33% 28.98 $5.88B 0.00%

About ADMA

ADMA stock trades at $8.71 with a market capitalization of $2.02B. The stock is valued at a price-to-earnings (P/E) ratio of 12.17, price-to-book of 4.93, price-to-sales of 3.76. Over the past 52 weeks the stock has ranged between $7.21 and $20.46, and currently trades 57.4% below its 52-week high.

On profitability, ADMA generates a return on equity (ROE) of 43.30% — well above the market average, a sign of a high-quality business, return on capital employed of 40.04%, an operating margin of 40.57%, a net profit margin of 32.43%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides